Dose recommendations for anticancer drugs in patients with renal or hepatic impairment.
Krens SD, Lassche G, Jansman FGA, Desar IME, Lankheet NAG, Burger DM, van Herpen CML, van Erp NP.
Lancet Oncol. 2019 Apr;20(4):e200-e207. doi: 10.1016/S1470-2045(19)30145-7.
Dose recommendations for anticancer drugs in patients with renal or hepatic impairment: an update.
Giraud EL, de Lijster B, Krens SD, Desar IME, Boerrigter E, van Erp NP.
Lancet Oncol. 2023 Jun;24(6):e229. doi: 10.1016/S1470-2045(23)00216-4.
Pharmacokinetics of roxithromycin in renal and hepatic failure and drug interactions.
Periti P, Mazzei T.
J Antimicrob Chemother. 1987 Nov;20 Suppl B:107-12. doi: 10.1093/jac/20.suppl_b.107.
Acute Kidney Injury and CKD Associated with Hematopoietic Stem Cell Transplantation.
Renaghan AD, Jaimes EA, Malyszko J, Perazella MA, Sprangers B, Rosner MH.
Clin J Am Soc Nephrol. 2020 Feb 7;15(2):289-297. doi: 10.2215/CJN.08580719. Epub 2019 Dec 13.
HEPATIC and renal failure.
[No authors listed]
Am J Med. 1958 Jan;24(1):122-31. doi: 10.1016/0002-9343(58)90367-x.
Bioartificial organ support for hepatic, renal, and hematologic failure.
Maguire PJ, Stevens C, Humes HD, Shander A, Halpern NA, Pastores SM.
Crit Care Clin. 2000 Oct;16(4):681-94. doi: 10.1016/s0749-0704(05)70140-8.
Effect of experimentally induced hepatic and renal failure on the pharmacokinetics of topiramate in rats.
Matar KM, Tayem YI.
Biomed Res Int. 2014;2014:570910. doi: 10.1155/2014/570910. Epub 2014 Jun 9.
Acute Liver Failure.
Rajaram P, Subramanian R.
Semin Respir Crit Care Med. 2018 Oct;39(5):513-522. doi: 10.1055/s-0038-1673372. Epub 2018 Nov 28.
New concepts on the clinical course and stratification of compensated and decompensated cirrhosis.
D'Amico G, Morabito A, D'Amico M, Pasta L, Malizia G, Rebora P, Valsecchi MG.
Hepatol Int. 2018 Feb;12(Suppl 1):34-43. doi: 10.1007/s12072-017-9808-z. Epub 2017 Jul 5.
Protein intake in renal and hepatic disease.
Ambühl PM.
Int J Vitam Nutr Res. 2011 Mar;81(2-3):162-72. doi: 10.1024/0300-9831/a000056.
